AbbVie’s JUVMO (tavapadon) targets dopamine differently from older drugs and is expected in US pharmacies this month, the company says.
Link as first comment.
@longevitytech.bsky.social
@longevitytech.bsky.socialAbbVie’s JUVMO (tavapadon) targets dopamine differently from older drugs and is expected in US pharmacies this month, the company says.
Link as first comment.
@newsevoce.bsky.socialEUA aprovam remédio para Parkinson que age de jeito inédito no cérebro: Tavapadon é o primeiro medicamento a ativar de forma seletiva os receptores de dopamina D1 e D5. Em estudo, aumentou em mais de uma hora por dia o tempo em que os pacientes se movimentam bem. #Parkinson #Tavapadon
@pharmaphorum.bsky.socialThe first product from #AbbVie's $8.7 billion takeover of #Cerevel two years ago – #Parkinsonsdisease therapy #tavapadon – has been approved by the #FDA.
@neurologyadvisor.bsky.socialFlexible-dose #tavapadon significantly improved motor symptoms compared with placebo among patients with early #ParkinsonDisease, although the trial’s short duration limited conclusions about long-term safety and tolerability.